ALFA Finder| Revenue growth | 23% YoY in Q4 FY26; FY26 revenue ₹940.5 cr. |
|---|---|
| Margins | Q4 EBITDA margin expanded to 17.73% from 13.17% YoY. |
| Demand visibility | High; 203 State FDA approvals received for Indore facility. |
Growth
Q4 FY26 revenue grew 23% YoY to ₹252.1 cr; EBITDA increased 65.5% YoY to ₹44.7 cr.
Outlook
Targeting 5-10% market share in key geographies. Indore facility expected to reach EBITDA breakeven in FY26 and margin accretive state by FY27.
Risks
Structural operating model changes in the Sparsh division temporarily compressed Q3/Q4 revenue. High regulatory compliance risks for export markets.
Earnings Call filed with BSE, NSE: GUFICBIO. Summary written with AI assistance from the document.
Gufic BioSciences Ltd: key numbers
- Share price
- ₹478.55
- Market cap
- ₹4,799 Cr
- Revenue (annual)
- ₹944.0 Cr
- Net profit (annual)
- ₹64.21 Cr
- P/E (TTM)
- 65.3×Sector 43.8×
- Promoter holding
- 72.50%+0.00% QoQ
- FII holding
- 0.44%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gufic BioSciences Ltd
All →Gufic BioSciences Board Meeting Date
Gufic Biosciences gives notice of a board meeting on 14 November 2026 to consider unaudited standalone and consolidated quarterly results. The filing carries no financial figures or business decision.
Gufic BioSciences Legal & Regulatory
Gufic Biosciences' tax dispute moved after the ITAT remanded matters to the Assessing Officer. The residual Rs. 11.76 lakh demand will be redetermined in fresh assessment.
- Value
- ₹0.12 Cr
Gufic BioSciences Legal & Regulatory
Gufic Biosciences disclosed an ITAT Mumbai order for AY 2023-24 that set aside the CIT(A) findings and restored the matter to the Assessing Officer. No demand arises from the order, and the tax liability will be determined after fresh assessment.
Gufic BioSciences Business Update
Gufic Biosciences reported a USFDA pre-approval inspection at its Indore facility, concluding October 23, 2026. The inspection produced three Form 483 observations, now being addressed.
Gufic BioSciences Other Announcement
Gufic Biosciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Gufic BioSciences Legal & Regulatory
Gufic Biosciences received a favorable appellate order from the Income Tax Commissioner. This order deletes an income tax demand of Rs. 4.33 Crore.
- Value
- ₹4.33 Cr